Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Consensus Target Price from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been assigned a consensus recommendation of “Buy” from the five analysts that are currently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $6.00.

CNTX has been the subject of several recent analyst reports. William Blair reiterated an “outperform” rating on shares of Context Therapeutics in a report on Tuesday, April 29th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Thursday, May 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of Context Therapeutics in a research report on Friday, March 21st.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in Context Therapeutics during the fourth quarter valued at approximately $29,000. Citadel Advisors LLC bought a new position in shares of Context Therapeutics in the fourth quarter valued at approximately $31,000. Shay Capital LLC bought a new position in shares of Context Therapeutics in the fourth quarter valued at approximately $52,000. Clear Harbor Asset Management LLC raised its position in shares of Context Therapeutics by 60.6% in the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock valued at $61,000 after purchasing an additional 21,804 shares during the period. Finally, Landscape Capital Management L.L.C. bought a new position in shares of Context Therapeutics in the fourth quarter valued at approximately $94,000. Institutional investors own 14.03% of the company’s stock.

Context Therapeutics Price Performance

Shares of CNTX opened at $0.71 on Tuesday. Context Therapeutics has a one year low of $0.55 and a one year high of $2.75. The company has a 50-day moving average of $0.78 and a two-hundred day moving average of $1.05. The stock has a market cap of $63.36 million, a price-to-earnings ratio of -0.78 and a beta of 2.11.

Context Therapeutics (NASDAQ:CNTX) last announced its earnings results on Wednesday, May 14th. The company reported ($0.05) EPS for the quarter, hitting the consensus estimate of ($0.05). Analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current year.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.